ClinicalTrials.gg
CompletedNCT02272517Updated Feb 28, 2017

Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine 10-20 mg and Escitalopram 10-20 mg in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed at 16 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
41st of 54
101 · median 413
Started
2014
with 3 others
Phase 3
31 of 54
1 open now
Registered
25th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 41st largest by enrollment, is one of 4 that started in 2014, is one of 31 in phase 3, and was the 25th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Vortioxetine
  • Cognition
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has MDD, diagnosed according to ™ recurrent MDE (classification 296.3x) as confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has depressive symptoms currently considered as non- or only partially responsive (inadequate response), to one adequate course of SSRI/SNRI antidepressant monotherapy and is candidate for a switch in the investigator's opinion.
  • The patient wants to stop taking his/her current SSRI/SNRI treatment due to inadequate response confirmed by the Antidepressant Treatment Response Questionnaire (ATRQ), \<50% response to current treatment).
  • The patient must have been treated by SSRI/SNRI monotherapy (citalopram, paroxetine, sertraline, duloxetine, or venlafaxine) for at least 6 weeks at licensed doses prior to the Screening Visit.
  • The patient has a PHQ-9 total score ≥14.
  • The patient has a MADRS total score ≥ 22.
  • The patient has had the current MDE for ≤1 year.
  • The patient has a Perceived Deficits Questionnaire - Depression (PDQ-D) total score >25.
  • The patient is a man or woman aged ≥18 and ≤65 years.

Exclusion criteria

Exclusion Criteria:

  • The patient has a score ≥70 on the DSST (Number of Correct Symbols) at the Baseline Visit.
  • The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • The patient has any current psychiatric disorder or Axis I disorder (according to DSMIV-TR™ criteria) other than MDD, as assessed using MINI.
  • The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of current episode (™ criteria).
  • The patient has borderline, schizotypal, schizoid, paranoid, histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
  • The patient has history of previous MDEs considered as treatment resistant defined as inadequate response (incomplete or no therapeutic response) to two prior courses of at least 6 weeks of conventional antidepressant drugs in adequate dosages or, the patient has treatment-resistant depression in the investigator's judgement.
  • The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient has a diagnosis of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) (DSM-IV-TR™ criteria) that has not been in sustained full remission at least 2 years prior to the Screening Visit.
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).

Other protocol defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Active comparator
    Escitalopram 10-20 mg

    Encapsulated tablets once daily for 8 weeks

    Drug: Escitalopram 10-20 mg

  • Experimental
    Vortioxetine 10-20 mg

    Encapsulated tablets once daily for 8 weeks

    Drug: Vortioxetine 10-20 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Digit Symbol Substitution Test (DSST)

    The DSST is recognised as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Rey Auditory Verbal Learning Test (RAVLT)

    Learning \[acquisition\] and memory \[delayed recall\])

    Time frame: Baseline to Week 8

  2. Change in Trail Making Test A (TMT-A)

    Speed of processing

    Time frame: Baseline to Week 8

  3. Change in Trail Making Test B (TMT-B)

    Executive functioning

    Time frame: Baseline to Week 8

  4. Change in Reaction time score; CRT attention

    Time frame: Baseline to Week 8

  5. Change in reaction time score SRT - simple reaction time

    Time frame: Baseline to week 8

  6. Change in STROOP incongruent score

    Executive functioning

    Time frame: Baseline to Week 8

  7. Change in STROOP congruent score

    Speed of processing

    Time frame: Baseline to Week 8

  8. Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score

    Patient-reported cognitive function outcome including attention concentration, retrospective memory, prospective memory, and, planning organization

    Time frame: Baseline to Week 8

  9. Change in Patient Health Questionnaire-9 (depressive symptoms) (PHQ-9) total score

    Patient-reported outcome

    Time frame: Baseline to Week 8

  10. Change in Clinical Global Improvement - Severity (CGI-S)

    Time frame: Baseline to Week 8

  11. Clinical Global Improvement (CGI-I)

    Time frame: Week 8

  12. Change in Functioning Assessment Short Test (FAST)

    Time frame: Baseline to Week 8

  13. Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score

    Time frame: Baseline to Week 8

07

Study locations

16 sites
  • FI005
    Helsinki, Finland
  • FI001
    Kuopio, Finland
  • FI006
    Kupio, Finland
  • FI007
    Tampere, Finland
  • FI004
    Turku, Finland
  • DE005
    Bochum, Germany
  • DE004
    Mittweida, Germany
  • RS002
    Belgrade, Serbia
  • RS003
    Belgrade, Serbia
  • RS004
    Belgrade, Serbia
  • RS005
    Belgrade, Serbia
  • RS001
    Kragujevac, Serbia
  • SK004
    Bratislava, Slovakia
  • SK001
    Hronovce, Slovakia
  • SK003
    Levice, Slovakia
  • SK002
    Rimavska Sobota, Slovakia
08

References and documents

Publications

  • Christensen MC, Sluth LB, McIntyre RS. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings. J Affect Disord. 2019 Feb 15;245:508-516. doi: 10.1016/j.jad.2018.11.034. Epub 2018 Nov 5. PubMed 30439678 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Mar 2016, 15 months.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 15 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2014
First posted
Oct 23, 2014
StartActual
Dec 2014
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02272517
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 23, 2014
Start date
Dec 2014
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Feb 28, 2017

Study contacts

Email contact via H.Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion